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ABSTRACT 
Early tumors, including high grade dysplasia and intramucosal invasive cancer, of the 
esophagus can today be removed using endoscopic resection, often using a technique called 
endoscopic submucosal dissection (ESD). This treatment is better tolerated and has 
considerably less mortality and morbidity compared to conventional, more invasive surgery, 
which usually entails esophagectomy. However, after larger endoscopic dissections, stricture 
formation is a common complication. Such strictures are usually treated with balloon 
dilatations, but the procedure often has to be repeated several times and is associated with 
risks such as perforations. In recent years, Japanese researchers developed a new method to 
reduce the risk of strictures. About two weeks before the treatment, an oral mucosa biopsy is 
taken from the patient from which epithelial cells are isolated and grown on special 
temperature-responsive polymer-coated surfaces. The polymer changes morphology and 
wettability properties depending on temperature, which enables non-enzymatic cell 
harvesting – the cells can be detached as contiguous sheets and with a large amount of 
extracellular matrix (ECM) maintained. After the ESD, cell sheets can be transplanted to the 
wound bed without the need for suture or other fixative, it is thought that the remaining ECM 
acts as a glue. Nine patients were treated in Tokyo and we subsequently transferred the 
technology to Stockholm where five additional patients were treated. Although one of nine 
patients in the Japanese cohort and three of five patients in the Swedish cohort still developed 
strictures, they appeared to be milder and easier to treat than expected. However, the aim of 
these projects was to evaluate safety and feasibility, further studies are needed to evaluate 
efficacy of the treatment. 
Since some patients still developed strictures despite the cell sheet transplantation, we next 
aimed to evaluate if exosomes from the cell culture media could be used as a pro-regenerative 
agent, perhaps in combination with cell sheet therapy. Media was collected from clinical-
grade production of cell sheets from eight healthy donors. The media was concentrated by 
ultra-filtration and exosomes were isolated by size-exclusion chromatography. The exosomes 
were characterized by western blot (CD9+, Flotillin-1+, GRP94-), electron microscopy and 
nanoparticle tracking analysis (~125 nm). They reduced the proliferation of skin fibroblasts 
and stimulated upregulation of gene expression of growth factors relevant for wound healing. 
We studied the exosomes’ adhesion to esophageal wound bed by topical application to 
porcine esophageal wounds ex vivo and could detect signal after as little as one minute 
adhesion time. We also found that the exosomes stimulated wound healing of full-thickness 
skin wounds in immunocompetent rats, both at the 6th day and 17th day time point. In 
conclusion we found that exosomes could be isolated from cell sheet media and that they 
exhibited pro-regenerative properties even in a xenogeneic setting. Further studies are 
necessary to evaluate their potential to stimulate mucosal wound healing and reduce stricture 
formation of the esophagus.  
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1 INTRODUCTION 
This thesis involves two very exciting, but also very complex research fields: regenerative 
medicine and extracellular vesicles (EVs). In this chapter, I will first briefly explain our 
clinical problem which is esophageal strictures developed after endoscopic submucosal 
dissections. I will then give an introduction to regenerative medicine and EVs. 
1.1 ESOPHAGEAL STRICTURES AFTER ENDOSCOPIC SUBMUCOSAL 
DISSECTION 
Today, early esophageal tumors or dysplasia can effectively be removed by endoscopic 
means, providing a much less invasive treatment compared to conventional surgery. The first 
technique was developed in the late 1980s, named endoscopic mucosal resection (EMR)1,2. In 
principle, a saline-based liquid is injected in the submucosa, to elevate the lesion. The lesion 
is then inserted into a snare which can be closed to resect the tissue. EMR has been shown to 
be safer than conventional surgery (esophagectomy), with considerably lower mortality and 
morbidity1. One of the limitations of EMR is that larger lesions cannot be removed en bloc 
(in one piece) which is more favorable for histopathological analysis to confirm radical 
resection. For this reason, endoscopic submucosal dissection (ESD) was developed. The 
lesion’s margins are first marked, and a liquid is injected in the submucosa. A special electric 
knife is then used to dissect the lesion en bloc from the underlying muscular layer3–5.  
A common complication after ESD is stricture formation, resulting in a decrease of the 
esophageal lumen which leads to dysphagia. The risk of stricture formation is related to the 
size of the dissection, especially the percentage of esophageal circumference (Fig 1) – a 
dissection involving 75% - 99% of the circumference was found to have a stricture rate of 
around 36%. In the cases where the whole circumference was dissected, 83% of the patients 
developed strictures4. Strictures can be treated by endoscopic balloon dilatation (EBD), but 
this often has to be repeated which impacts the patients’ quality-of-life (QOL) and there is a 
significant risk of esophageal perforation due to the dilatations6,7. 
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Figure 1- Grading of esophageal mucosal defects.  
Reproduced with permission from: Funakawa K et al. Effect of Submucosal Dissection for Superficial Esophageal Neoplasms 
and Risk Factors for Postoperative Stricture. Medicine (Baltimore). 2015. 94(1):e373. 
https://insights.ovid.com/pubmed?pmid=25569662 
Prevention of such post-ESD strictures remains a clinical challenge. Several methods have 
been reported but none has yet gained general acceptance8. In principle, the tried methods fall 
into four different categories: I) corticosteroids (local injection9 or systemic administration10), 
II) stent11 / prophylactic dilatations12, III) tissue engineering solutions (cell based13 or 
biomaterial14,15 based), IV) other (for example small interfering RNA16 or botulinum toxin17 
injections).   
1.1.1 Steroid treatment 
Corticosteroids are thought to prevent stricture formation by reducing collagen synthesis and 
stimulating collagen degradation. The treatment is cost-effective but steroid treatment, 
especially systemic, has adverse effects including risk of infections, diabetes, osteoporosis 
etc8. System treatment is generally administered for at least three weeks. Another method 
involves local injections into the wound bed, which will likely reduce the risk of adverse 
effects, but the treatments have not been found to reduce the frequency of strictures, although 
some researchers suggest that the severity of the developed strictures is reduced8.  
1.1.2 Prophylactic stenting 
Stents can be placed after the ESD, in order to prevent the development of strictures. Studies 
have reported successful outcomes, but, the risk of stent migration is considerable. The stents 
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can be made from degradable or non-degradable material, and in some cases the stents are 
drug-eluting. However, in general, the sample-sizes in the published studies are too small to 
draw any strong conclusions8.   
1.2 REGENERATIVE MEDICINE 
The fact that the parts of the human body can 
regenerate has been known for a long time. A 
good example is that of the Greek mythology 
titan Prometheus (Fig 2) who stole fire from 
the gods and gave it to the humanity. As a 
punishment, the gods sentenced him to 
eternal suffering, he was bound to a rock and 
an eagle would feed on his liver every day. 
By the following day, the liver had 
regenerated and the eagle could once again 
feed. Interestingly, despite the liver being one 
of the most regenerating organs in the human 
body, being able to regenerate after surgical 
removal of 2/3 of its volume, expanding 
hepatocytes in vitro is very challenging18. 
There is no globally accepted definition of 
regenerative medicine, but the aim is 
commonly stated to be to repair or replace 
damaged, injured or missing tissue with methods such as administering cells (cell therapy), 
applying biomaterials or a combination of the two (tissue engineering). Regenerative 
medicine is a relatively new research field, which is thought to have been used for the first 
time in 199219. Since year 2000 there has been an enormous increase of interest in the field, 
with over 7000 articles published in 2018 (Fig 3). 
 
Figure 3 - Number of publications with key words "Regenerative Medicine". Data from 
https://www.ncbi.nlm.nih.gov/pubmed/ 
Figure 2 - "Prometheus Bound" by Peter Paul Rubens, 1618.  
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1.2.1 Cell therapy 
1.2.1.1 Hematopoetic stem cell transplantation 
Hematopoetic stem cell transplantation (HSCT) as a treatment for leukemia represent a 
success story which was first performed in patients by Dr Donall Thomas in 195720 and today 
is a clinical routine treatment. Dr Thomas shared the Nobel Prize in Physiology or Medicine 
with Dr Joseph Murray in the year 1990. During the years, the indications for the treatment 
has widened, and today include both hematopoetic and solid tumors21. The general principle 
of the treatment is to first reduce the diseased bone marrow using chemotherapy and / or 
irradiation treatments. Subsequently, donor (or in some cases the patients’ own) cells are 
infused, with the hope that they will engraft and eliminate any residual malignant cells. In 
some cases, this does not happen, and remission is never achieved. A common complication 
to HSCT is graft-versus-host disease (GVHD), where the infused cells are reacting with the 
recipient tissue, typically causing symptoms in mucosa and skin22. Many of the GVHD cases 
can be managed by pharmacological treatment using corticosteroids, but steroid-refractory 
GVHD is a very severe condition with high mortality rates. The absence of treatments for 
these patients led to the development of a new cell therapy method using mesenchymal 
stromal cells (MSCs)23. 
1.2.1.2 Mesenchymal stromal cells for steroid-refractory GVHD 
The interest for MSCs has been enormous and the cells have been isolated from a variety of 
tissues including bone marrow24, adipose and skeletal muscle tissue25. These cells have been 
found to be pro-regenerative, immunomodulatory and well tolerated in allogeneic setting. 
Subsequently, researchers have tried to use them for many indications, for example, liver 
fibrosis26, skeletal muscle regeneration27, lung injury28,29 and many others30–35.  
Due to the lack of treatment options for patients with steroid-refractory GVHD, Ringdén and 
colleagues investigated the use of MSCs for this indication. Bone marrow was harvested from 
donors, mononuclear cells were isolated through Redigrad gradient separation and the cells 
plated and maintained in incubators. Finally, the cells were resuspended in phosphate 
buffered saline (PBS) with 10% human plasma, and administered to the patients through 
infusion. In six of eight patients, the GVHD disappeared completely, and the survival rate 
was significantly better than controls23. Today there are several completed and ongoing 
clinical studies based on these findings. However, according to a recent Cochrane systematic 
review, the evidence today is not strong enough to support a conclusion that the treatment is 
effective36. Hopefully, larger trials with more participants will shed light on the efficacy of 
the treatment.  
1.2.1.3 Chimeric Antigen Receptor-T-cells 
This very exciting approach was developed in recent years. In brief, a cancer patient’s T-cells 
are isolated and genetically engineered to target tumor antigen. This is achieved by 
introducing a synthetic antigen-recognizing receptor to the T-cells. The cells are then 
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expanded and infused to the patient37. This treatment was developed by Israeli researcher 
Zelig Eshhar in 1993 and by 2017, FDA approved the first CAR-T-based therapy, targeting 
acute lymphoblastic leukemia which was developed by Novartis38. The treatment is now 
under investigation for other indications, including diffuse large B-cell lymphoma, multiple 
myeloma and chronic lymphocytic leukemia37,39.  
1.2.2 Tissue engineering 
While cell therapy generally consists of injection or infusion of single cell suspensions, tissue 
engineering adds another dimension by including some sort of structure, usually referred to as 
a scaffold.  In principle, any adherent cell can be used, and the scaffold can be either of 
synthetic / artificial or biologic origin. Regardless of the origin of the scaffold, the aim is to 
have a structure that resembles the target tissue, can support and direct cell growth and permit 
(or even better stimulate) ingrowth of blood vessels. Of course, the scaffold should be non-
immunogeneic, and where necessary, suturable to enable surgical implantation. Artificial 
scaffolds can be created in many different ways, for example electrospinning40–44 or 3D-
printing45–50. Biological scaffolds are often created by removing cells from donor tissue, so 
called decellularization51,52. Using different reagents, often detergents and enzymes, cells can 
be removed from the tissue without disrupting the underlying extracellular matrix (ECM). 
The ECM can often retain similar mechanical properties to the native tissue but at the same 
time be biocompatible as the immunogenic elements are removed. Cells can subsequently be 
seeded and cultured onto the ECM surface (Fig 4). 
 
Figure 4 - Scanning electron microscopy of mesenchymal stromal cell growing on decellularized tissue.  
Source: private 
One of the groundbreaking examples in this field was the ex vivo construction of a beating 
heart. Ott and colleagues decellularized rodent hearts and could observe macroscopical 
beating after reseeding the scaffolds with cells53. The same technique was later used to create 
bioartifical lungs which were capable of contributing to gas exchange54. Other researchers 
have used similar methodology to regenerate blood vessels51,55,56, kidneys57, esophagus58,59, 
cornea60 and aortic valves61. 
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1.2.2.1 The “Vacanti mouse” 
In 1997, one of the early examples of tissue engineering was conducted by the group of Dr 
Vacanti, in which they aimed to create a cartilage structure resembling an external ear. An 
artificial scaffold was used, consisting of polyglycolic acid-polylactic acid shaped to resemble 
an external ear of a 3-year-old child. The scaffolds were seeded with chondrocytes from 
bovine articular cartilage and were incubated for one week, after which they were implanted 
subcutaneously in athymic mice. Non-seeded scaffolds served as controls. They found that 
chondrocytes could adhere to and survive on the scaffold in vitro. In the seeded scaffolds, 
neo-cartilage observation 
could be observed after in 
vivo implantation, no neo-
cartilage was found in the 
non-seeded scaffolds. They 
also found that an external 
stent was necessary to keep 
the three-dimensional 
structure. The image of the 
so called “ear-mouse” or 
“Vacanti-mouse” has 
become a symbol for tissue 
engineering (Fig 5). Dr 
Vacanti predicted that the 
image would lead to 
controversy and avoided to 
share images of the mouse 
with journalists62. 
However, the image still 
reached the media and 
allegedly sparked protests 
against genetic engineering 
– despite that no genetic 
engineering was involved in the research.   
1.2.2.2 Bladder and genital organs 
Roughly a decade after the Vacanti mouse, urologist Anthony Atala made a breakthrough in 
urinary bladder tissue engineering. The team had constructed transplantable structures made 
from collagen or collagen-polyglycolic acid composite, seeded with autologous urothelial 
and muscle cells. The transplantations were done in seven patients and had positive 
functional outcomes (decreased mean bladder leak points, increase of volume and compliance 
etc)63. Eight years later, the same group published the use of a similar technology to create 
vaginal organs in patients with congenital aplasia. The follow-up period was up to eight years 
and there was functional restoration including gain of sexual function64.  Professor Atala 
Figure 5 - "Vacanti mouse" – one of the early examples of tissue engineering.  
Reproduced with permission from: Cao, et al. Transplantation of chondrocytes utilizing 
a polymer-cell construct to produce tissue-engineered cartilage in the shape of a human 
ear. Plast. Reconstr. Surg. 1997. 100(2): 297-302. 
https://insights.ovid.com/pubmed?pmid=9252594 
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could also successfully replace a large portion of rabbit penises by using autologous cells 
seeded on collagen scaffolds. The functional outcomes were remarkable: the animals 
receiving the grafts could impregnate female rabbits65.  
1.2.2.3 Esophageal mucosa regeneration 
This example of tissue engineering has the same aim as our cell sheet project which will be 
mentioned in section 1.2.3.2, and in article two of this thesis. Early tumors or high-grade 
dysplasia of the esophagus can today be removed by endoscopic resection. However, a 
common complication after larger resections is stricture formation. Professor Badylak has 
developed a method of applying a tubularized sheet of xenogeneic ECM (derived from 
porcine small intestine). In this article, five patients underwent an endoscopic treatment 
whereby circumferential, long segment mucosa was removed. The biological scaffold was 
then held in place by a stent, which was removed after 9-18 days when the scaffold had 
integrated to the native tissue. Although all five patients developed strictures, they were 
limited to areas that were not covered by the scaffold and the authors conclude that the 
treatment had a beneficial effect and stimulated constructive remodeling66.  
1.2.3 Cell sheet engineering 
In mid-1990s, Prof Okano described the novel use of a temperature-responsive polymer for 
use in cell cultures. The polymer Poly(N-isopropylacrylamide) changes conformation and 
wettability based on temperature: in 37 °C, the polymer, covalently attached to cell culture 
surface, is around 20 nm and hydrophobic. However, when the temperature is lowered below 
32 °C, the polymer transforms to 60 nm and becomes hydrophilic. Cells can grow on the 
surface in a heated incubator, but once the temperature is lowered, the cells will detach67. 
Conventionally, cells are detached / harvested using enzymatic treatment, for example 
trypsin. However, using these enzymes commonly damages various proteins, including cell-
to-cell connections and ECM. Harvesting the cells using temperature reduction results in 
contiguous cell sheets, with maintained cell-to-cell connections68 and ECM69. For 
transplantations, the sheets readily adhere to the target tissue, without the need of sutures or 
tissue glue70,71, which likely is due to the maintained ECM69. The cell sheet technology has 
been used for a variety of indications such as cardiac68,72, osteoarthritis73 and liver 
applications74. Following, I will describe three clinical applications.    
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1.2.3.1 Cell sheets for corneal replacement 
There is a constant turnover of corneal epithelial cells, with a renewing of cells stemming 
from progenitor cells in the vascularized limbus area. Loss of these cells, so called limbal 
stem cell deficiency can lead to vascularization of the cornea and irregular epithelium, with 
subsequent discomfort and impaired vision. Common treatments are autologous 
transplantation of limbal cells from the opposite eye or transplantation of donated cornea. 
However, in some cases the injury is 
bilateral and there is a constant lack of 
available donors. This led Dr Nishida and 
colleagues to explore possible solution 
through cell sheet technology. They 
investigated the use of oral mucosal 
keratinocytes due to their similarities to 
corneal epithelium, the availability of 
these cells and the fact that buccal grafts 
had been used in ocular surgery before. 
Four patients with total limbal stem-cell 
deficiency were included. Biopsies were 
taken from the patients’ oral mucosa, 
epithelial cells isolated and grown into 
cell sheets. Fourteen days after the biopsy, the cell sheets were ready to be transplanted. The 
corneal stroma was surgically re-exposed and the cell sheet was placed directly onto the 
stromal bed. The sheets attached without any suturing. All four patients had improved corneal 
transparency and visual acuity, and transparency remained during the mean follow-up of 14 
months (Fig 6). No complications were found70.  
1.2.3.2 Cell sheets for esophageal stricture prevention 
Researchers at Tokyo Women’s Medical University aimed to reduce the risk of stricture 
formation of the esophagus after ESD. The technique was first evaluated in a canine model. 
Oral mucosal epithelial cells were isolated and grown into cell sheets. ESD wounds, 5 cm 
long and 180° of the esophageal circumference, were made and half of the animals received 
cell sheet treatment. The sheets adhered to the wound bed within ten minutes and without any 
sutures or clips. The transplanted cells could be detected on the eighth day. The wounds that 
were treated with cell sheets were completely healed at four weeks, in contrast to the control 
wounds that still were in an intermediate wound healing phase. Similarly, the treated wounds 
were completely re-epithelialized, while control wounds were not. Further the amount of 
inflammatory cells in the wounds were considerably higher in the controls75. 
Figure 6 - Cell sheet transplantation for cornea regeneration. 
Reproduced with permission from (Nishida, K. et al. Corneal 
reconstruction with tissue-engineered cell sheets composed of 
autologous oral mucosal epithelium), Copyright Massachusetts 
Medical Society. 
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After the promising results from the canine study, Dr Ohki and colleagues aimed to study 
safety and efficacy of the treatment by an open-label, single-arm and single-institution 
study71. Nine patients received the cell sheet treatment after ESD (Fig 7). Cell sheets could be 
manufactured from the biopsies from each patient. Two to eight cell sheets were transplanted 
and follow-up were performed by endoscopic evaluation and by dysphagia scoring (Mellow-
Pinkas score). The dissected circumference ranged from ½ to “almost whole” (patient 4) (Fig 
8), and dissected area from 231 mm2 to 3850 mm2. Patient 4 developed a stricture that was 
treated with 21 balloon dilatations, while the remaining patients had a favorable outcome 
without strictures or dysphagia. The authors conclude that the wound healing was faster than 
their previous experience (3.5 vs 4 weeks, 
except for patient 4 = 16 weeks). 
Transplanted cells could be detected one 
week after transplantation, but this was only 
evaluated in one patient.   
I joined Tokyo Women’s Medical 
University for a research exchange program 
in 2010 and was introduced to the esophagus 
project. In 2011, the transfer of this 
technology to Karolinska Institutet and 
Karolinska University Hospital was initiated. 
The report of the first five patients, described 
in 2016, is “article 1” of this thesis76 and will 
be discussed in detail under chapter 4.  
Later, a new collaborative project was 
started between Nagasaki University 
Hospital and Tokyo Women’s Medical 
University6. The aim was to study the 
feasibility of air-transportation of biopsy and 
cell sheets between the two sites, a distance 
of 1200 kilometer. This technique could 
enable cell sheet transplantation almost all 
over Japan, regardless of whether the 
hospital has the technical capacity to 
manufacture cell sheets or not. Ten patients 
were included, cell sheets could successfully 
be manufactured in Tokyo and transported 
back to Nagasaki. The authors also found 
that the cell sheets produced vascular 
endothelial growth factor (VEGF) and 
interleukin-12.  
Figure 8 - Stricture formation despite cell sheet 
transplantation.   
Reprinted from Gastroenterology 2012. 143(3), Ohki, et al., 
Prevention of Esophageal Stricture After Endoscopic 
Submucosal Dissection Using Tissue-Engineered Cell Sheets, 
582-588, Copyright (1012), with permission from Elsevier 
Figure 7 - Cell sheet transplantation, no stricture formation. 
Reprinted from Gastroenterology 2012. 143(3), Ohki, et al., 
Prevention of Esophageal Stricture After Endoscopic 
Submucosal Dissection Using Tissue-Engineered Cell Sheets, 
582-588, Copyright (1012), with permission from Elsevier 
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The ESDs were in general larger than the patients transplanted in Tokyo. Circumference 
ranged from 5/6 of the circumference to complete circumference, and the area ranged from 
1350 to 7985 mm2. Three of the patients also received radiotherapy due to lymphovascular 
invasion and submucosal invasion (SM2). After one week, all cell sheets could be observed 
and were accompanied with vascularization. However, after two weeks, the sheets were not 
detectable. Four of the patients developed post-ESD strictures, requiring a maximum of seven 
balloon dilatations. Otherwise, no significant adverse effects were observed during the 
median follow-up time of 105.5 weeks. Although four patients developed strictures, the 
authors indicate that the risk was lower compared to similar subsets of patients where the 
incidence was 90%. However, the authors acknowledge that further controlled studies are 
necessary to verify the efficacy of the treatment compared with corticosteroids. 
1.3 EXTRACELLULAR VESICLES 
Originally, the main function of extracellular vesicles (EVs), was thought to be waste 
removal – basically a way for cells to get rid of unwanted cargo77. However, in recent years 
the vast functions of EVs have gained the interest of many researchers. EVs can transport 
protein, lipids and nucleic acids between cells and are important in both physiological and 
pathological states78. The vesicles are enclosed by a lipid bilayer and include transmembrane 
proteins79. EVs can generally be divided into three main categories, microvesicles, apoptotic 
bodies and exosomes80. Microvesicles are generated by an outward budding of the cell 
membrane and roughly have a diameter of 50 – 1,000 nm. Apoptotic bodies are larger (500 – 
2,000 nm), are also produced by an outward budding of the cell membrane, but in this case 
from apoptotic cells80. Exosomes, on the other hand, are smaller (less than 150 nm), and 
produced in several steps. First, an inward budding of the cell membrane produces an 
endosome, and inward budding of that endosome produces multivesicular bodies (MVBs) 
filled with smaller vesicles (termed exosomes). Once the MVBs fuse with the cell membrane, 
the exosomes are released into the extracellular space (Fig 9).  
EVs are highly complex and contain many component including membrane protein, lipids, 
adhesion molecules, enzymes and nucleic acids78. They can transmit signals to target cells 
through receptor-ligand binding or through absorption by phagocytosis, endocytosis or fusion 
with cell membrane (Fig 9)79. EVs can be used in many different fields of biomedical 
research, from diagnostics81–85, investigating biological processes86 and therapeutics87–90.  
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1.3.1 Clinical applications of extracellular vesicles as therapeutics 
The use of exosomes or EVs as therapeutics is still a new field and there are only few clinical 
examples. Besse and colleagues reported the use of small EVs derived from dendritic cells for 
end-stage cancer91, with the aim to boost the patients’ T-cell and natural killer cell (NK-cell) 
immune response. The indication was inoperable non-small cell lung cancer. The primary 
end-point, progression-free survival 4 months after chemotherapy cessation in 50% of 
patients, was not met, but the authors conclude that the exosomes could boost the patients’ 
antitumor immunity.  
Based on the rationale that MSCs can be used for severe graft-vs-host disease (GVHD), and 
that this effect likely could be driven by secreted factors, a German group treated one patient 
with MSC-exosomes87. The group isolated exosomes from four different donors and used in 
vitro assays to determine which of the donors’ exosomes that were most suitable, based on 
immunomodulatory and anti-inflammatory properties. The exosomes were administered to 
the patient and the dose was increased every second day, in total seven administrations were 
Figure 9 – Extracellular vesicle biogenesis and target cell interaction.  
Reprinted by permission from Springer Nature: Nature Reviews Drug Discovery 
(Extracellular vesicles: biology and emerging therapeutic opportunities, El Andaloussi et 
al.), Copyright Springer Nature 2013 
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performed. No adverse effects were found. The patient’s pro-inflammatory cytokine response 
reduced during the treatment course and his GVHD-symptoms improved considerably within 
two weeks. The patient was stable for several month, but unfortunately passed away seven 
months after the treatment. Although an interesting case, the results from one single patient 
have to be carefully interpreted.   
2 THESIS AIMS 
2.1 PAPER I 
The aim of this paper was to evaluate the safety and feasibility of using oral mucosal 
epithelial cell sheet-transplantation after esophageal ESD in a Western population. The 
technology was transferred from Tokyo Women’s Medical University to Karolinska Institutet 
and Karolinska University Hospital. Regarding my own contribution to the project, I was 
assisting in the technology transfer and preparation of regulatory documents. I also studied 
clinical-grade cell sheets that were not transplanted regarding histological architecture, ECM-
composition, viability, cell proliferation etc, aiming to further characterize and assess the 
general health of the transplanted cell sheets.  
2.2 PAPER II 
The primary aim of this paper was to investigate if culture media from clinical-grade cell 
sheet production could be used as a source of therapeutic exosomes. Considering that some 
patients still develop stricture, despite the cell sheet transplantation, we wanted to investigate 
if these exosomes could have a regenerative effect, and possibly be used in combination with 
cell sheets. Additionally, we believed that this project could improve our understanding of the 
mode-of-action of these cell sheets. The isolated exosomes were analyzed in vitro and in vivo.  
2.3 PAPER III 
In Paper II, we found that exosomes from the cell sheet cultures had pro-regenerative effects 
in vitro and in vivo. However, these exosomes have two origins, they are both derived from 
the oral keratinocytes and from the autologous serum. In this paper we used commercially 
available cells (gingival epithelial cells) to prepare conditioned medium without serum, thus 
generating a purer exosome isolate. The aim was to understand more of the exosome-cell 
interactions.   
3 METHODOLOGY 
Detailed description of the methods used is available in each paper. Here, I will briefly and 
discuss key methods used in the papers.  
3.1 CELL SHEET PRODUCTION AND QUALITY CONTROL 
Oral mucosal biopsies were obtained from patients (paper I) and healthy donors (paper II). 
The samples were sent, together with autologous serum, to cell processing center (Vecura, 
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Stockholm for paper I, CellSeed Inc, Tokyo for paper II). Cell isolation and cultures were 
performed under strict, clinical grade conditions. For quality control, detachment tests were 
performed, and cell numbers, viability and purity were assessed. Endotoxin and 
microbiological testing was also performed.   
3.2 HUMAN DONORS 
All five patients in paper I and eight healthy donors in paper II were male, aged 56-70. A 
more diverse population would have been favorable, or even better, matched controls 
between male and females, so any gender differences could have been investigated. 
Hopefully, future studies can shed light on any gender-specific differences.   
3.3 EXTRACELLULAR VESICLE ISOLATION 
There are various ways to isolate EVs, each with pros and cons. We decided to use a 
combination of ultrafiltration and size exclusion chromatography. Cells and debris were 
removed from the conditioned media using centrifugation or 0.22 µm filtration. The media 
was then concentrated using ultrafiltration, in order to reach a volume that fit the size 
exclusion chromatography columns (500 µl). These columns are driven by gravity – the 
sample is loaded onto the columns and will pass through a gel. The gel has small pores (70 
nm) wherein smaller molecules will enter, and thus take longer time to pass the gel. Vesicles, 
which do not enter the pores as easily, will pass through the gels quicker and be diluted in the 
first fractions. This is an easy and quick method to isolate vesicles from bulk protein. Of 
course, it is impossible to completely exclude all bulk protein, why a better term probably is 
“exosome / EV enrichment”.  
3.3.1 Isolation from cell sheet media 
Optimally, serum free media is used to produce the conditioned media. The reason for this is 
that serum also contains vesicles, meaning that the final isolate will not be purely derived 
from the cultured cells. In the case of paper I, this was not possible as we had to follow the 
already established clinical-grade production protocols, which includes 5% autologous 
serum. The isolated exosomes in this project are therefore a mix of cell culture-derived 
exosomes and serum derived exosomes. This would have been suboptimal if the primary aim 
of the project was to understand the mode-of-action of the cells. However, our primary aim 
was to investigate whether “waste-products” from clinical grade cultures could be 
transformed into a therapeutic agent, so in this case the “less pure” exosomes are acceptable. 
We also included exosomes from non-conditioned media, entirely derived from the 
autologous serum, to act as a control  
3.3.2 Isolation from gingival keratinocytes 
For paper III, we performed the cell cultures in our own institute. Unfortunately, we couldn’t 
get the same cells that were used in paper II (from healthy volunteers), as these were used in 
other experiments. Instead we used commercially available cells derived from gingiva. 
Although these cells also are derived from oral mucosa, there are differences, for example, 
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the buccal mucosa has a higher turnover time than other tissues in the oral cavity92. How this 
affects the exosomes is difficult to predict. 
3.4 NOMENCLATURE – EXOSOMES OR SMALL EXTRACELLULAR 
VESICLES 
In paper II and III, we refer to the isolated (or enriched) vesicles as exosomes. This was based 
on a paper in Cell from 2016, which describes exosomes as vesicles with a diameter less than 
150 nm. Paper II and III were mainly written during 2018 and in November 2018, the 
International Society for Extracellular Vesicles published updated guidelines about EV 
research93. In principle, they state that since specific markers for each vesicle subtype does 
not (yet) exist, researchers should avoid using subtype terms, including “exosomes”. In 
hindsight, it would have been more appropriate to name the vesicles described in paper II and 
III as “small extracellular vesicles” (sEVs). For consistency, I refer to the vesicles less than 
150 nm diameter as exosomes in this thesis.  
3.5 SIZE DISTRIBUTION OF EXOSOMES 
According to a statement paper from the international society for extracellular vesicles94, size 
distribution should be measured using suitable techniques. This hardware was not available at 
the institute where the research was performed, so we had to rely on collaborators for these 
analyses. This unfortunately led to the use of two different techniques for paper II and III, 
which makes comparing the results more complicated. In paper II we used nanoparticle 
tracking analysis (NTA) which briefly is performed by illuminating the particle suspension 
with laser and recording the light which is scattered by the particles. Video clips are recorded 
and it is then possible to calculate the size of the particles based on Brownian motion (the 
random motion of the particles is depending on the particle size). The NTA also calculates 
the concentration of particles in the solution.  
For paper III we used a different technology, tunable resistive pulse sensing (TRPS). In this 
technique, the particle solution is passed through a nanoscale pore and the ionic current flow 
through the pore is recorded. When the particle is passing through the pore, there is a 
blockage of the ionic current flow, and from this signal, the size, charge and concentration of 
particles can be calculated.   
3.6 ADHESION ASSAY TO ARTIFICIAL ESOPHAGEAL WOUND BED EX VIVO 
This experiment was performed in order to evaluate the feasibility of the potential to use 
these exosomes after esophageal ESD. Perhaps the exosome solution could be sprayed onto 
the wound bed which was not covered by cell sheets. But considering the patients’ 
swallowing of saliva, would the exosomes remain in the intended location? This was the 
background of this assay where we added labelled exosomes to artificial ulcers in healthy pig 
esophageal tissue. After pipetting the exosomes onto the wound bed, we let them adhere for 
1, 2 or 5 minutes, after which it was completely submerged and washed in PBS, and 
visualized under a fluorescent dissection microscope.  
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3.7 SKIN WOUND MODEL 
As mentioned previously, the aim of paper II was to investigate if waste product (used / 
excess culture media) could be transformed into a therapeutic agent to be used in conjunction 
with cell sheets to prevent esophageal strictures. Naturally, a model where these exosomes 
were used on actual esophageal wounds would have been logical. So, why did we choose to 
perform skin wounds instead? There were several reasons. First of all, we had no idea if the 
hypothesis would hold. Surely, exosomes have been used several times for wound healing90 
and other regenerative medicine applications95. But, to our knowledge, exosomes derived 
from oral mucosal epithelial cells had never been analyzed in similar settings. Secondly, skin 
wounds can be performed in a more control fashion compared to esophageal wounds. 
Previous esophageal wounds for cell sheet therapy used large animals, which also represent a 
greater cost, effort and animal suffering. Additionally, those wounds were much larger than 
the ones we created in the rats (thus requiring more exosomes), and our supply of exosomes 
was very limited, as they were derived from donors. For these reasons we decided to continue 
with a model that was easier to control, and where the wounds could be smaller.   
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RESULTS 
In this chapter I will discuss the findings of each paper in a broader perspective than what’s 
already described in the papers. Paper I describes the safety and feasibility of oral mucosal 
epithelial cell sheets for stricture prevention. In paper II, we confirmed that exosomes derived 
from conditioned media from such cell sheets stimulate wound healing, even in a xenogeneic 
setting. In paper III, we described the gingival keratinocyte-derived exosome isolation, 
uptake and regulation of cell proliferation.  
3.8 PAPER I 
The cell sheet technology for esophageal application could successfully be transferred to 
Sweden. From each of the included patients, oral mucosal epithelial cell sheets could be 
produced, all meeting the defined product specifications. The dissections were 75 – 100% 
and 5 – 10 cm long, three were due to adenocarcinoma (T1a and T1b) and two were due to 
Barrett’s mucosa with high-grade dysplasia. Cell sheets could successfully be transplanted to 
all patients. Probe-based confocal laser endomicroscopy (pCLE) indicated that transplanted 
areas hosted epithelial cells, while non-transplanted areas mostly were covered by fibrin. 
pCLE also indicated that the cell sheets remained healthy on the transplant site, and that 
intrapapillary capillary loops (IPCLs) could not be detected in the regenerated mucosa, up to 
four weeks after ESD. Evaluation of IPCLs has been suggested to be a diagnostic tool for 
esophageal carcinoma96, the relevance of their absence in this case, or if they regenerate at a 
later stage, remains unclear. The mucosal defects healed within a mean time of three weeks 
and the three patients with 100% circumferential dissections developed strictures. The aim of 
this project was not to evaluate the efficacy of the treatment, but the clinicians’ opinions were 
that the strictures were easier to treat than what would’ve been expected.  
The evaluations of excess cell sheets consisted of histology, immunohistochemistry, gene 
expression analysis, functional assays and transmission electron microscopy (TEM). The 
sheets were evaluated after that they had been transported to the operating theater and found 
to be excessive. This means a minimum of 30 minutes in room temperature and normal air 
(compared to 5% CO2 atmosphere in the incubator). Hence, the status of the sheets better 
reflected the status of transplanted sheets, compared to sheets being analyzed straight in the 
production facility. We found that the cells were metabolically active and with few dead 
cells. The sheets were 3-5 cells thick and proliferative cells were found in the basal part of the 
sheets, resembling the structure of an epithelium. Compared to fibroblasts, the cells had an 
upregulation of epithelial marker keratin 18, and pluripotency markers OCT4 and SOX2, 
while NANOG could not be detected. Immunohistochemistry revealed retained ECM-
proteins collagen I and IV, elastin and laminin. Laminin was more strongly expressed in the 
basal parts, also consistent with a normal epithelium. Connexin 43 and TEM-imaging suggest 
maintained gap junctions. It would have been interesting to compare the cell sheets to cells 
harvested though enzymatic treatment such as trypsin, in terms of gap junctions and ECM-
proteins, to confirm that these properties are more highly maintained by cell sheet 
technology. 
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Pluripotency markers SSEA4, C-kit, Oct-4 and Sox-2 were also identified on protein level.  
The biopsies used to isolate the cells are full-thickness mucosal samples, and thus include 
cells from the basal part of the epithelium. Researchers at TWMU were unsuccessful to 
produce cell sheets from “swabs” or brushings of the oral mucosa, possibly due to the 
absence of proliferative cells which are more basal. Other researchers have also reported that 
the lamina propria of the oral mucosa harbors a stem cell population97.  
3.9 PAPER II 
Since some patients still developed stricture despite cell sheet transplantation, we here aimed 
to transform used or excessive culture media from the cell sheet production, into a therapeutic 
agent that possibly could be used in combination with cell sheets. We received both unused 
(non-conditioned) and conditioned media from healthy donors. The yield was approximately 
2 µg exosomes / mL and 1 µg exosomes / mL for non-conditioned (“ncExo”) and conditioned 
(“cExo”) respectively. The yielded number of particles per milliliter showed the same pattern, 
but without significant difference, which is likely due to fewer data points (n=3 each). These 
results were surprising, we expected the opposite results – higher yield in the cExo, as the 
keratinocytes are releasing exosomes during the culture. It could be explained by that 
exosomes are internalized and degraded by the cells during the culture, to a higher extent than 
they produce. 
Total protein measurements and gel electrophoresis showed that the majority of bulk-proteins 
diluted in “non-EV”-fractions from the size-exclusion chromatography. Albumin, the most 
abundant protein in serum, could effectively be separated from the exosome preparations. 
Using western blot, we detected two markers that are expected to be enriched in EV-
preparations: CD9 and Flotillin-1 and negativity for GRP94, which is a marker for 
endoplasmic reticulum (common contaminant). We confirmed the morphology by TEM and 
size distribution by NTA. Taken together, we could effectively isolate exosomes with 
undetectable levels of contaminants.  
We used fibroblasts in our in vitro studies because they are key cells in the formation of 
strictures98 as well as scars99. We also included dexamethasone as a control substance as it is 
also used clinically to prevent stricture formation of the esophagus8. We first studied the 
proliferation of fibroblasts. Exosomes from both groups effectively reduced cell proliferation, 
but cExo was in general more effective. We used fraction 12 from the chromatography to test 
“non-EV-proteins” and found that their effect was considerably lower. Neither cExo nor 
ncExo showed any cytotoxicity towards the fibroblasts.  
Exposure to exosomes from both groups led to a large increase of gene expression for several 
growth factors relevant for wound healing: hepatocyte growth factor (HGF), vascular 
endothelial growth factor A (VEGFA), fibroblast growthfactor-2 (FGF2) and connective 
tissue growth factor (CTGF). cExo gave a higher response in general, but only significantly 
for HGF. Dexamethasone, did only increase the expression of CTGF. HGF, VEGFA and 
FGF2 are in general thought of being “pro-regenerative” growth factors. CTGF, on the other 
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hand, is more complex. It is known to promote fibrosis and can have both pro- and anti-
angiogenic effects100. Whether the increase of CTGF is an advantage or not in our case 
remains unknown. The increase of HGF was also confirmed on protein level.  
Since cells from the oral mucosa has been shown to have antibacterial properties101, we 
investigated if the exosomes could have similar effect. We could see a small, but significant, 
reduction of S. aureus at the 3h time point, and only with cExo, not ncExo.  
Next we evaluated if exosomes could adhere to “ESD-ulcers” – we used biopsy punches to 
create small wounds in the mucosa of porcine esophagus. We found that the exosomes 
adhered to the tissue very quickly, we could detect a positive signal even after only one 
minute adhesion. For in vivo experiments, we used cutaneous, full-thickness wound healing 
in immunocompetent rats. Signal from the exosomes could be detected until the sixth day.  
We applied two protocols, one where 7.6 µg of exosomes were applied, divided on day 0 and 
day 1, and a second protocol where 12.5 µg were delivered only on day 0. The animals were 
sacrificed on day 6. There was no difference between the groups when comparing 
macroscopic wound areas (measured from macroscopic digital photos). Images of 
histological sections were analyzed by two blinded, independent researchers, revealing that 
cExo accelerated wound healing (reduced wound width), especially from protocol 1. ncExo 
showed no effect using protocol 1, but some reduction from protocol 2. That protocol 1 was 
more effective, despite a lower total dose, suggest that repeated administration is of higher 
importance than dose. We proceeded with a 17-day time point for protocol 1 and found that 
cExo significantly reduced the wound width, while ncExo had no effect. These in vivo 
experiments were done in a xenogeneic setting: human-derived exosomes applied to 
immunocompetent, Sprague-Dawley rats.  
In a hypothetic clinical scenario, the yield would not be enough to administer the same dose 
(7.6 µg / 0.1963 cm2 ≈ 38.7 µg / cm2). Based on Ohki’s paper71, the average area was around 
14 cm2, which would require about 542 µg and based on the yield of approximately 0.96 µg / 
mL conditioned media, we would need 520 mL media. One cell sheet has 4 mL media, and 
conditioned media could be collected eight time  520 / (4 x 8) = 16.25 sheets. That is more 
than the number of sheets usually produced per patient (which was as low as three sheets for 
one patient in paper I). However, this is just a hypothetical calculation and perhaps even 
lower doses could be effective.   
3.10 PAPER III 
After the promising results from paper II, we here wanted to understand more about the oral 
keratinocyte derived exosomes. It has been shown that exosomes from mesenchymal stromal 
cells can stimulate the growth of tumor cells102,103. Since we potentially would use the oral 
keratinocyte after ESD for esophageal cancer, it could be a safety concern, if the exosomes 
stimulated any residual malignant cells to grow. We also aimed to understand more of the 
mode-of-action of the cell sheets. In this study, we could get a more pure isolation of 
exosomes, as we could remove the serum from the media.  
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We compared exosomes from gingival oral keratinocytes and skin fibroblasts. Buccal 
keratinocytes (same origin as for paper II), would have been more suitable but we could not 
acquire such. Measured as µg vesicles produced per million cells per 24h, the yield was 
higher from keratinocytes compared to fibroblasts. However, when yield was calculated as 
number of particles released, there was an opposite trend. This suggest that the keratinocyte-
derived exosomes (OKex) had more protein per particle compared to fibroblast-derived 
exosomes (FEx). Both groups showed similar morphology and size distributions. When 
studying exosome-uptake into fibroblasts or keratinocytes, we could detect signal after as 
little as 90 minutes, and all groups were positive at the 16 hour time point. The exosomes are 
small and are not detectable by themselves under light or fluorescent microscope. The dots 
that are seen in the figures likely represent aggregations of a large amount of exosomes. The 
uptake is probably even faster than the 90 minutes that we found, just that our methodology is 
not sensitive enough.  
In order to understand more of the mode-of-action of the cell sheets, we used fibroblasts and 
keratinocytes as target cells – both which are abundant and important in healing of wounds. 
Both groups of exosomes reduced the proliferation of fibroblasts, and higher dose had a 
stronger effect. The effect at the highest tested dose was similar to that of dexamethasone. For 
keratinocytes, the effect was a little bit more complex. OKEx showed an “inversed dose-
dependency”, where a higher dose had smaller effect than lower doses.  FEx suppressed the 
proliferation more strongly and at similar levels for the tested concentrations.  
We also tested two tumor cell lines. For HaCaT-cells, OKEx suppressed the proliferation at 
doses over 150 ng / mL, while at the other doses there was no significant change compared to 
control (no exosomes). FEx reduced the proliferation at most tested concentrations (strangely 
not at 300 ng / mL). Dexamethasone effectively suppressed the proliferation as well. Next we 
examined TR146, a carcinoma cell line with its primary tumor in the buccal mucosa. OKex 
reduced the proliferation at 600 ng / mL, and did not affect the proliferation at lower doses. 
FEx suppressed the proliferation at 75 and 18.75 ng / mL, but had no effect at other doses. 
Interestingly, for these cells, dexamethasone did not affect the proliferation.  
One question regarding this study might be why we didn’t use the same concentration of 
exosomes in the in vitro assays, as we used in paper II. The reason for this is that since we 
anyway didn’t know what proportion of the exosomes were derived from the cell sheet 
compared to the serum, it would anyway be impossible to compare the results.  
We believe that the above results, where OKEx often showed similar results to 
dexamethasone, could indicate one part of the mode-of-action of the cell sheet therapy. The 
results between the two groups of exosomes were similar, so could we use fibroblast sheets 
instead? That would possibly not be a good idea, based on the fact that strictures (and scars) 
show an abundancy of fibroblasts, basically, we aim to prevent excessive amount of 
fibroblasts in the tissue – transplanting more could defeat the purpose. The findings that 
OKEx suppressed the proliferation of two tumor cell lines would add to the safety profile of 
the use of OKEx after ESD, although this should be studied in more tumor cell lines.   
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4 FUTURE PERSPECTIVES 
In paper I, we described the use of autologous oral mucosal epithelial cell sheets to reduce the 
risk of esophageal strictures. The therapy is currently very costly, mainly due to the cell sheet 
production costs. Steroid treatment, on the other hand, represents a very low cost. Currently, 
it is not known which is the better therapy, but for cell sheets to become a standard treatment, 
my guess is that the production cost has to be greatly reduced. To my understanding, the big 
portion of the costs come from the large amount of required manual labor. Automatization by 
robotics is currently being developed in Japan and could potentially reduce the costs 
significantly. The costs can also likely be reduced if the production volume goes up. Another 
potential idea is to explore the use of allogeneic cells, which would reduce the number of 
necessary steps in the production.  
We found in paper II that exosomes derived from conditioned media could stimulate wound 
healing to a larger extent than exosomes from non-conditioned media. Although we found 
some differences in our in vitro assays, the reason for the differences remain unclear. We are 
currently planning for proteomic and sequencing studies of these exosomes, which hopefully 
could shed light on the differences of these two samples.  
Another interesting finding was that repeated administration of exosomes was more 
important than the dose. For future studies, it would be interesting to evaluate some sort of 
slow-releasing systems for in vivo applications, for example based on hydrogels. In our 
studies, we evaluated the wound healing histologically earliest on day 6. Re-epithalialization 
had already occurred in all groups. It would be interesting to try a shorter time point. 
Additionally, it would be interesting to study the histological sections more in detail, in order 
to evaluate differences in the regeneration of structures such as nerves, blood vessels, skin 
adnexa etc. 
As mentioned under 4.3, several tumor cell lines should be studied, especially esophageal 
tumor cells. Finally, an esophagus injury model would be very interesting.   
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